PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024)

PRF Technologies (PRFX) posted quarterly Net Income towards Common Stockholders of -$7.6 million for Q2 2024, down 204.12% year-on-year from $7.3 million in Q3 2023, and down 30.63% on a QoQ basis from -$5.8 million in Q1 2024.

PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends

PRF Technologies (PRFX) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$7.6 million the latest figure, recorded in Q2 2024.

  • Quarterly Net Income towards Common Stockholders fell 204.12% year-over-year to -$7.6 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$7.6 million (up 68.54% YoY) and the FY2025 annual result came in at -$5.0 million, up 66.16% from the prior year.
  • Net Income towards Common Stockholders slipped to -$7.6 million in Q2 2024 per PRFX's latest filing, from -$5.8 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for PRFX reached as high as -$700000.0 in Q3 2020 and fell as low as -$10.7 million in Q4 2023.
  • A 5-year average of -$3.7 million and a median of -$2.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 31.46% — and 2024, when it tumbled 204.12%.
  • Year by year, Net Income towards Common Stockholders stood at -$4.2 million in 2020, then sank by 65.42% to -$6.9 million in 2021, then decreased by 28.75% to -$8.9 million in 2022, then retreated by 21.01% to -$10.7 million in 2023, then rose by 29.24% to -$7.6 million in 2024.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.6 million, -$5.8 million, and -$10.7 million for Q2 2024, Q1 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 PRF Technologies 706,290.59 -3.43 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2024 -7.60 Mn
Mar 31, 2024 -5.82 Mn
Dec 31, 2023 -10.74 Mn
Sep 30, 2023 -1.60 Mn
Jun 30, 2023 -2.50 Mn
Mar 31, 2023 -2.66 Mn
Dec 31, 2022 -8.88 Mn
Sep 30, 2022 -2.34 Mn
Jun 30, 2022 -2.08 Mn
Mar 31, 2022 -1.91 Mn
Dec 31, 2021 -6.89 Mn
Sep 30, 2021 -2.00 Mn
Jun 30, 2021 -1.88 Mn
Mar 31, 2021 -2.04 Mn
Dec 31, 2020 -4.17 Mn
Sep 30, 2020 -700,000.00
Jun 30, 2020 -969,000.00
Mar 31, 2020 -1.59 Mn